Galapagos NV
Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
| Formerly | Galapagos Genomics NV |
|---|---|
| Company type | Naamloze vennootschap |
Traded as | Euronext Amsterdam: GLPG BEL 20 component |
| ISIN | BE0003818359 |
| Industry | Pharmaceutical |
| Founded | 1999 |
| Headquarters | Mechelen, Belgium |
Key people | Paul Stoffels (CEO) Raj Parekh (Chairman) |
| Products | Filgotinib; GLPG1205; GLPG0778 |
| Revenue | €288.836 million (2018) |
Net income | €-29.259 million (2018) |
| Total assets | €1,439.496 million (2018) |
| Total equity | €1,214.249 million (2018) |
Number of employees | 725 (2018) |
| Website | www |
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.